Overview
Background
Dr Keane is a haematologist at Princess Alexandra Hospital and runs the Lymphoma Research Lab at the UQDI in Brisbane. His main research interest is focused on the interface between the tumour microenvironment and the malignant lymphoma cell, with a goal to build an understanding of lymphoma from an immunological and biomarkers perspective. To bridge developments between the clinic and bench-top, the laboratory has a strong emphasis on patient material, which it obtains from international and national clinical collaborators, much being from investigator-led clinical trials.
Lymphomas studied include more common lymphomas such as Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma and Follicular Lymphoma but his lab has a particular focus on rare lymphomas such as primary central nervous system lymphoma and lymphomas that develop in patients who are immunocompromised.
Dr. Keane has been instrumental in translating work from his lab into multiple immune based clinical trials currently being run across Australia, many in rare and hard to treat lymphomas, where patients have limited treatments available.
The goals of the lab are to directly improve outcomes for all lymphoma patients by performing innovative translational science that not only generates new knowledge and brings new treatments to Australian patients but helps to train the next generation of lymphoma researchers in Australia.
Availability
- Associate Professor Colm Keane is:
- Available for supervision
Qualifications
- Masters (Coursework) of Business Administration, Griffith University
- Doctor of Philosophy, Griffith University
Research interests
-
Tumour Immunology
-
DLBCL
-
Primary CNS Lymphoma
-
Hodgkin Lymphoma
-
Viral Associated Lymphomas
Works
Search Professor Colm Keane’s works on UQ eSpace
2023
Journal Article
Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma
Gandhi, Maher K. and Keane, Colm (2023). Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma. Haematologica, 108 (12), 3195-3196. doi: 10.3324/haematol.2023.283392
2023
Conference Publication
Polatuzumab, Bendamustine & Rituximab Efficacy In Relapsed/refractory Trial‐ineligible Large B Cell Lymphoma Patients: An Australian Lymphoma Registry (LARDR) Study
Shaw, B., Chung, E., Wellard, C., Yoo, E., Bennett, R., Birks, C., Johnston, A., Cheah, C., Hamad, N., Simpson, J., Barraclough, A., Ku, M., Viiala, N., Ratnasingam, S., Armytage, T., Cochrane, T., Chong, G., Lee, D., Manos, K., Keane, C., Wallwork, S., Opat, S. and Hawkes, E. (2023). Polatuzumab, Bendamustine & Rituximab Efficacy In Relapsed/refractory Trial‐ineligible Large B Cell Lymphoma Patients: An Australian Lymphoma Registry (LARDR) Study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3165_572
2023
Conference Publication
Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse
Swain, F., Burgess, M., Kempe, S., Sabdia, M., Wight, J., Hawkes, E., Mutsando, H., Talaulikar, D., Merida de Long, L., Hawula, Z., Birch, S., Wyche, P., Gandhi, M. K. and Keane, C. (2023). Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_191
2023
Conference Publication
Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B‐cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” study
Hawkes, E. A., Palmer, J., Chong, G., Lee, S., Keane, C., Shortt, J., Scott, A. M., Churilov, L., Macmanus, M., Smith, C., Barraclough, A., Khor, R. and Manos, K. (2023). Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B‐cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_448
2023
Conference Publication
An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment
Lavie, D., Johnson, N., Borchmann, P., Herrera, A. F., Avigdor, A., Gasiorowski, R., Gregory, G., Keane, C., Vucinic, V., Bazargan, M., Herishanu, Y., Minuk, L., Tzoran, I., Andreadis, C., Armand, P., Kuruvilla, J., Zinzani, P. L., West, R. Marceau, Pillai, P., Marinello, P. and Timmerman, J. (2023). An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_263
2023
Conference Publication
Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma
Tobin, J. W., Tsang, H., Patch, A., Keane, C., Law, S. C., Gunawardana, J., Blombery, P., Thompson, E. R., Sabdia, M. B., De Long, L. M., Nath, K., Kazakoff, S. H., Cheah, C., Amanuel, B., Cochrane, T., Butler, J., Johnston, A., Shanavas, M., Li, L., Shelton, V., Hershenfeld, S., Kridel, R., Seymour, J. F., MacManus, M. and Gandhi, M. K. (2023). Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_189
2023
Conference Publication
T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR study
Koldej, R. M., Barraclough, A., Lee, S. T., Morgan, H., Holzwart, N., Koshy, M., Smith, C., Chong, G., Gilbertson, M., Keane, C., Ting, S., Churilov, L., Ritchie, D. S. and Hawkes, E. A. (2023). T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_183
2023
Journal Article
Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia
Burgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631
2023
Journal Article
A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma
George, Hannah, Gunawardana, Jay, Keane, Colm, Hicks, Rod J. and Gandhi, Maher K. (2023). A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma. Internal Medicine Journal, 53 (7), 1105-1109. doi: 10.1111/imj.16078
2023
Journal Article
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry
Nguyen, James, Wellard, Cameron, Chung, Eliza, Cheah, Chan Y., Dickinson, Michael, Doo, Nicole Wong, Keane, Colm, Talaulikar, Dipti, Berkahn, Leanne, Morgan, Susan, Hamad, Nada, Cochrane, Tara, Johnston, Anna M., Forsyth, Cecily, Opat, Stephen, Barraclough, Allison, Mutsando, Howard, Ratnasingam, Sumita, Giri, Pratyush, Wood, Erica M., McQuilten, Zoe K. and Hawkes, Eliza A. (2023). Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. European Journal of Haematology, 110 (4), 386-395. doi: 10.1111/ejh.13915
2023
Journal Article
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort
Agrawal, Prashasti, David, Kevin A., Chen, Zhengming, Sundaram, Suchitra, Kim, Seo-Hyun, Vaca, Ryan, Lin, Yong, Singer, Samuel, Malecek, Mary-Kate, Carter, Jordan, Zayac, Adam, Kim, Myung Sun, Reddy, Nishitha, Ney, Douglas, Habib, Alma, Strouse, Christopher, Graber, Jerome, Bachanova, Veronika, Salman, Sidra, Vendiola, Jean A., Hossain, Nasheed, Tsang, Mazie, Major, Ajay, Gandhi, Maher K., Keane, Colm, Bond, David A., Folstad, Matthew, Chang, Julie, Mier-Hicks, Angel ... Martin, Peter (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia and Lymphoma, 64 (5), 1026-1034. doi: 10.1080/10428194.2023.2191152
2023
Journal Article
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study
Manos, Kate, Chong, Geoffrey, Keane, Colm, Lee, Sze-Ting, Smith, Charmaine, Churilov, Leonid, McKendrick, Joseph, Renwick, William, Blombery, Piers, Burgess, Melinda, Nelson, Niles Elizabeth, Fancourt, Tineke, Hawking, Joanne, Lin, Wendi, Scott, Andrew M., Barraclough, Allison, Wight, Joel, Grigg, Andrew, Fong, Chun Yew and Hawkes, Eliza A. (2023). Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. Leukemia, 37 (5), 1092-1102. doi: 10.1038/s41375-023-01863-7
2022
Journal Article
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
Baggio, Diva, Wellard, Cameron, Chung, Eliza, Talaulikar, Dipti, Keane, Colm, Opat, Stephen, Giri, Pratyush, Minson, Adrian, Cheah, Chan Yoon, Armytage, Tasman, Lee, Denise, Chong, Geoffrey, Johnston, Anna, Cochrane, Tara, Waters, Neil, Hamad, Nada, Wood, Erica M. and Hawkes, Eliza A. (2022). Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. Leukemia & Lymphoma, 64 (3), 621-627. doi: 10.1080/10428194.2022.2157676
2022
Conference Publication
Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tsoran-Rosenthal, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166670
2022
Conference Publication
Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166846
2022
Journal Article
Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry
Lymphoma and Related Diseases Registry Investigators, Gandhi, Maher K. and Keane, Colm (2022). Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Medical Research Methodology, 22 (1) 266, 1-10. doi: 10.1186/s12874-022-01728-0
2022
Conference Publication
Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890800.36906.bb
2022
Conference Publication
Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Borchmann, Peter, Johnson, Nathalie A., Lavie, David, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890812.66186.e8
2022
Conference Publication
Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma
Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17
2022
Journal Article
Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance
Keane, Colm, Hamad, Nada, Barraclough, Allison, Lee, Yoo Y., Talaulikar, Dipti, Ku, Matthew, Wight, Joel, Tatarczuch, Maciej, Swain, Fiona and Gregory, Gareth P. (2022). Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 52 (9), 1624-1632. doi: 10.1111/imj.15658
Funding
Current funding
Past funding
Supervision
Availability
- Associate Professor Colm Keane is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Investigating the mechanisms of immune evasion in relapsed/refractory DLBCL
Principal Advisor
Other advisors: Dr Zachary Hawula
-
Doctor Philosophy
Investigation of immune responses to novel and standard therapies in DLBCL
Principal Advisor
Other advisors: Dr Joshua Tobin, Associate Professor Fernando Guimaraes
-
Doctor Philosophy
Immuno-genetic biomarkers of response in a prospective study of immune checkpoint therapy in primary CNS lymphoma
Principal Advisor
Other advisors: Dr Arutha Kulasinghe, Dr Zachary Hawula
-
Doctor Philosophy
Impact of genetics upon the tumour microenvironment in Follicular Lymphoma
Associate Advisor
Other advisors: Dr Joshua Tobin, Dr Soi Law, Professor Maher Gandhi
-
Master Philosophy
Amyloidosis Monitoring and Outcomes in an Australian Tertiary Centre
Associate Advisor
-
Doctor Philosophy
Reversing tumour necrosis factor-mediated immunosuppression to boost immunity against experimental CD19+ blood cancers
Associate Advisor
Other advisors: Dr Allie Lam, Associate Professor Fernando Guimaraes
Completed supervision
-
2022
Doctor Philosophy
A Comprehensive Study of Intratumoural T-cells in Follicular Lymphoma
Associate Advisor
Other advisors: Dr Soi Law, Professor Maher Gandhi
-
2021
Doctor Philosophy
Clinical and Prognostic Tools to Improve Frontline Management Strategies in Follicular Lymphoma
Associate Advisor
Other advisors: Professor Maher Gandhi
-
2020
Doctor Philosophy
The impact of deficient antigen presentation on the tumour microenvironment of diffuse large B cell lymphoma
Associate Advisor
Other advisors: Professor Maher Gandhi
-
2019
Doctor Philosophy
A LABORATORY STUDY OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Associate Advisor
Other advisors: Professor Maher Gandhi
Media
Enquiries
For media enquiries about Associate Professor Colm Keane's areas of expertise, story ideas and help finding experts, contact our Media team: